April 18, 2026 New England Journal of Medicine, Volume 394, Issue 15: Key Insights from Pages 1553–1554, April 16, 2026
April 18, 2026 Revolution Medicines’ Daraxonrasib Doubles Survival in Pancreatic Cancer Phase 3 Trial